Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients

Novartis

Status: Completed

Conditions: Metastatic Melanoma

Study type: Observational

Funder types: Industry

Identifiers

NCT06369428

CDRB436BFI02

Details and patient eligibility

About

This was a retrospective, non-interventional, registry study based on secondary electronic medical record (EMR) data collected in Helsinki and Uusimaa hospital district (HUS data lake), hospital district of Southwest Finland (VSSHP data lake) and Pirkanmaa hospital district (PSHP data lake) as a part of their routine clinical practice. Social Insurance Institution of Finland (SII; reimbursed drug purchases) was utilized in this study to complement the medication data. The metastatic melanoma patients were stratified by first-line treatment and by hospital district.

Enrollment: 1,795 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

• Patients diagnosed with metastatic melanoma (C43) during 01 January 2014 and 31 December 2021.
• Adult (18 years or older) at the time of diagnosis of metastatic melanoma.
• Resident in the corresponding hospital district(s) at the time of diagnosis of metastatic melanoma.

Exclusion criteria

• Metastasis recorded prior to 01 January 2014 (i.e. prevalent case).
• Record of any other cancer (The International Classification of Diseases, 10th Revision [ICD-10] diagnosis code starting with C, excluding C43, C77, C78, and C79) as last cancer diagnosis before metastasis.
• Participated in COBRA (vemurafenib, temozolomide, lomustine, vincristine) trial.

Trial design

1,795 participants in 2 patient groups

Distant Metastasis Cohort

Description:

Adult patients diagnosed with stage 4 (distant) metastatic melanoma between 2014 and 2021.

Regional Metastasis Cohort

Description:

Adult patients diagnosed with stage 3 (regional) metastatic melanoma between 2014 and 2021.